Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

AstraZeneca advances its ambition to redefine hematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, ...
Forbes

Best Free Budgeting Apps In 2026: Compare Our Top Picks

Budgeting apps, many of which are cost-free for the basic version, track outgoing spend and make it easier to identify where cutbacks can be made. So whether you’re attempting to budget for the first ...
KTEN

Number's up: Calculators hold out against AI

The humble pocket calculator may not be able to keep up with the mathematical capabilities of new technology, but it will ...